Outcomes of Interest
Outcomes of interest included baseline demographics (age, sex, US region, type of health insurance, and presence of other biologic-treated conditions), treatment history (use of biologic and non-biologic psoriasis treatments during the baseline period), and most frequent diagnostic (International Classification of Diseases, 10th revision [ICD-10]) and procedural (Current Procedural Terminology [CPT] and Healthcare Common Procedure Coding System [HCPCS]) claims during the baseline period.
Statistical Analysis
Categorical variables were summarized using frequencies or percentages and continuous variables were summarized using means and standard deviations. All analyses were conducted using SAS for Windows 9.4 (Cary, NC).
RESULTS
Baseline Characteristics
A total of 1,520 patients with psoriasis who had initiated guselkumab during the study period were identified (Figure 1). The baseline demographics for these patients are presented in Table 1. The mean age was 51.2 (SD 13.4) years and 53.7% of patients were female. The largest proportion of patients was from the Southern US (41.3%) and the most common type of insurance at index was commercial (63.3%). Psoriatic arthritis (PsA) was the most common comorbid biologic-treated condition identified during the baseline period (14.9%).
Prior Pharmacy Claims
During the baseline period, 972 patients (63.9%) had ≥1 biologic drug claim and 206 patients (13.6%) had claims for ≥2 biologics.
A total of 1,520 patients with psoriasis who had initiated guselkumab during the study period were identified (Figure 1). The baseline demographics for these patients are presented in Table 1. The mean age was 51.2 (SD 13.4) years and 53.7% of patients were female. The largest proportion of patients was from the Southern US (41.3%) and the most common type of insurance at index was commercial (63.3%). Psoriatic arthritis (PsA) was the most common comorbid biologic-treated condition identified during the baseline period (14.9%).
Prior Pharmacy Claims
During the baseline period, 972 patients (63.9%) had ≥1 biologic drug claim and 206 patients (13.6%) had claims for ≥2 biologics.
